Tvardi Therapeutics, Inc. (TVRD) – What Are Researchers Thinking About This Stock?

Posted by Geri Gentry on Nov 7th, 2026

Tvardi Therapeutics, Inc. (NASDAQ:TVRD – Get Free Report) has been assigned an average rating of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $9.40.

TVRD has been the topic of a number of research analyst reports. BTIG Research reduced their target price on Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Wall Street Zen cut shares of Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, November 1st. Chardan Capital started coverage on Tvardi Therapeutics in a report on Tuesday, October 20th. They issued a “buy” rating for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Friday, October 2nd. Finally, Lucid Cap Mkts upgraded shares of Tvardi Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 8th.

View Our Latest Report on Tvardi Therapeutics

Hedge Funds Weigh In On Tvardi Therapeutics

Hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new position in Tvardi Therapeutics during the second quarter worth about $181,000. Susquehanna International Group LLP purchased a new stake in Tvardi Therapeutics during the 2nd quarter valued at $63,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Tvardi Therapeutics in the second quarter worth about $34,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Tvardi Therapeutics Price Performance

Shares of TVRD stock opened at $0.96 on Friday. The business’s 50 day simple moving average is $1.28 and its 200 day simple moving average is $2.68. The stock has a market capitalization of $12.78 million, a PE ratio of -0.34 and a beta of 0.37. Tvardi Therapeutics has a one year low of $0.77 and a one year high of $5.69.

Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). As a group, research analysts expect that Tvardi Therapeutics will post -2.23 earnings per share for the current year.

Tvardi Therapeutics Company Profile

(Get Free Report)

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases involving abnormal STAT3 signaling. STAT3 is a protein that can contribute to tumor growth, treatment resistance and immune suppression, making it a potential target for drug development.

The company’s lead investigational product is TTI-101, an orally administered small-molecule inhibitor designed to block STAT3 activity. Tvardi is evaluating TTI-101 in clinical studies for solid tumors, including hepatocellular carcinoma and other advanced cancers.